Bariatek, founed by Truffle Capital in 2019, is a clinical-stage MedTech company dedicated to fighting obesity and diabetes, two pandemics affecting more than a billion patients worldwide. Their minimally invasive device, BariTon™, is implanted endoscopically in just a few minutes and reproduce the effects of bariatric surgery by inducing restriction and mal-absortion.